ArticleClinical pharmacology in drug development2023

Phase 1 Clinical Results for NP10679, a pH-sensitive GluN2B-selective N-methyl-d-aspartate Receptor Inhibitor.

Robert Zaczek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.